trial
as of 2026-07-01Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NCTId NCT01908192
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 60 (actual)
Sponsored by SyneuRx International (Taiwan) Corp
Primary completion 2023-10-26
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-06
Primary completion
2023-10-26
Eligibility
ALL · 12 Years · 17 Years
Interventions & indications
Drugs
Indications
Sponsors
SyneuRx International (Taiwan) CorpLead Sponsor
Investigators
1
Robert Findling, MDPrincipal Investigator
Sites
23 total
Dothan, United StatesBellflower, United StatesLong Beach, United StatesRiverside, United StatesHartford, United StatesWashington D.C., United StatesMiami, United StatesOrange City, United StatesAtlanta, United StatesBaltimore, United StatesWorcester, United StatesAnn Arbor, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
60
Phase
PHASE2,PHASE3
Primary Completion Date
2023-10-26
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person